People with color blindness may be less able to spot an early sign of bladder cancer, making them likelier to be diagnosed ...

On Jan. 20, 2026, investors weigh ImmunityBio’s sharp rally on new FDA feedback around its bladder cancer plans.

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B ...

A large U.S. health records study suggests that difficulty seeing blood in urine may put color-blind patients at higher risk.

ImmunityBio stock rose 19.8% after FDA meeting on ANKTIVA bladder cancer treatment. Company to submit additional data within ...

ANKTIVA is an Interleukin-15 (IL-15) receptor agonist that helps develop and activate key cells that work to destroy cancer ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

People who are colorblind may be missing a life-saving warning sign of bladder cancer. Analysis of the electronic health ...

Investing.com -- ImmunityBio Inc (NASDAQ:IBRX) stock surged 19.8% in premarket trading Tuesday after the company reported ...

ImmunityBio Inc. (NASDAQ:IBRX) shares climbed nearly 20% in premarket trading on Tuesday after the company said it held positive discussions with the U.S. Food and Drug Administration regarding its ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...